INNsight Newsletter - March edition

INNsight Newsletter - March edition

Welcome to the March edition of INNsight Newsletter, where we share with you the latest news and insights from?IQVIA Global Market Insights.?

This month's thought leadership includes:

  • CAR-T Cell Therapy in Cancer Treatment
  • M&A Activity Rebounds at the End of 2023
  • Global Trends in R&D 2024: Activity, Productivity, and Enablers
  • WEBINAR:??MIDAS Early Bird – Uncovering the Defining Trends of 2023 and What These Hold for 2024 (On-Demand)


CAR-T Cell Therapy in Cancer Treatment

Chimeric antigen receptor (CAR)-T cell therapy is a novel form of treatment that is emerging as a transformative approach in cellular immunotherapy. In 2021, the global market for CAR-T cell therapy was estimated to be 1.5 billion USD and it is forecasted to grow to approximately 7.6 billion USD by 2026, demonstrating a compound annual growth rate (CAGR) of 39.1%. Concurrently, the number of CAR-T clinical trials is on the rise, with continual improvements to the CAR-T constructs aimed at boosting their effectiveness and minimizing adverse outcomes.?Read more


M&A Activity Rebounds at the End of 2023

Mergers and acquisitions (M&A) in the biopharmaceutical sector experienced a notable resurgence in the fourth quarter of 2023, with an increase in both the overall deal value and volume of these transactions. Despite facing challenges such as macroeconomic factors and regulatory obstacles, biopharmaceutical companies actively pursued substantial M&A endeavors towards the end of 2023 with around 70% of these transactions carried out by big pharma companies and driven by novel, innovative therapies and technologies.?Read more


Global Trends in R&D 2024: Activity, Productivity and Enablers

This report assesses the trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The notable acceleration and adaptability of the innovation ecosystem is examined in terms of several enablers of R&D productivity, including the relationship between shortening trial durations and the ‘white space’ within clinical development timelines that have been reducing for some diseases and increasing for others.? Read more


ON-DEMAND WEBINAR:??MIDAS Early Bird: Uncovering the defining trends of 2023 and what these hold for 2024

This special webinar as we uncover the latest pharmaceutical market trends, from post-pandemic recovery to emerging therapy areas, recent launches and transformational developments. From physician engagement to oncology and immunology therapy areas, generics, biosimilars and the developments in diabetes and obesity markets. Don't miss it and stay ahead of the competition. Watch on-demand now


To learn about IQVIA Global Market Insights' solutions and how we can support your business, follow this link.


要查看或添加评论,请登录

社区洞察

其他会员也浏览了